BRAF inhibitors: The current and the future

Current Opinion in Pharmacology

Volumn 23, Issue , 2015, Pages 68-73

  Zhang, Weijiang ^a  

^a Roche Innovation Center New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; DACARBAZINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLX 7904; PLX 8394; PROTEIN KINASE B; RAF PROTEIN; RO 51267566; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ALOPECIA; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; ERDHEIM CHESTER DISEASE; FATIGUE; FEVER; HAIRY CELL LEUKEMIA; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERKERATOSIS; INOPERABLE CANCER; MELANOMA; METASTATIC MELANOMA; NAUSEA; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PAPILLOMA; PERSONALIZED MEDICINE; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SKIN PAPILLOMA; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FORECASTING; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FORECASTING; HUMANS; IMIDAZOLES; NEOPLASMS; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84930614384     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.05.015     Document Type: Review

References (43)

1. H. Davies, G.R. Bignell, and C. Cox Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
2. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, and A. McNabola BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
3. A. Hauschild, S.S. Agarwala, U. Trefzer, D. Hogg, C. Robert, and P. Hersey Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma J Clin Oncol 27 2009 2823 2830
4. K.T. Flaherty, I. Puzanov, and K.B. Kim Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
5. J.A. Sosman, K.B. Kim, and L. Schuchter Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
6. G.A. McArthur, P.B. Chapman, C. Robert, J. Larkin, J.B. Haanen, and R. Dummer Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Lancet Oncol 15 2014 323 332
7. V.A. Trinh, J.E. Davis, J.E. Anderson, and K.B. Kim Dabrafenib therapy for advanced melanoma Ann Pharmacother 48 2014 519 529
8. ® (Dabrafenib) US prescribing information. Research Triangle Park, NC: GlaxoSmithKline. http://us.gsk.com/products/assets/us-tafinlar.pdf.
9. ® (Vemurafenib) US prescribing information. South San Francisco, CA: Genentech USA, Inc. http://www. gene.com/download/pdf/zelboraf-prescribing.pdf.
10. S.J. Heidorn, C. Milagre, and S. Whittaker Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 140 2010 209 221
11. G. Hatzivassiliou, K. Song, and I. Yen RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464 2010 431 435
12. F. Su, A. Viros, and C. Milagre RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors N Engl J Med 36 2012 207 215
13. P.A. Oberholzer, D. Kee, and P. Dziunycz RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors J Clin Oncol 30 2012 316 321
14. R. Anforth, V. Tembe, T. Blumetti, and P. Fernandez-Peñas Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors Pigment Cell Melanoma Res 25 2012 569 572
15. P. Uribe, and S. Gonzalez Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy Pathol Res Pract 207 2011 337 344
16. C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz, D. Stroiakovski, M. Lichinitser, R. Dummer, F. Grange, and L. Mortier Improved overall survival in melanoma with combined dabrafenib and trametinib N Engl J Med 372 2015 30 39
17. G.V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, and J.J. Grob Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma N Engl J Med 371 2014 1877 1888
18. A. Ribas, R. Gonzalez, A. Pavlick, O. Hamid, T.F. Gajewski, A. Daud, L. Flaherty, T. Logan, B. Chmielowski, and K. Lewis Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study Lancet Oncol 15 2014 954 965
19. M. Sanlorenzo, and A. Choudhry Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma J Am Acad Dermatol 71 2014 1102 1109
20. K. Le, E.S. Blomain, U. Rodeck, and A.E. Aplin Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenibresistant melanoma cells Pigment Cell Melanoma Res 26 2013 509 517
21. K.J. Basile, K. Le, E.J. Hartsough, and A.E. Aplin Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors Pigment Cell Melanoma Res 27 2014 479 484
22. M. Yancovitz, A. Litterman, J. Yoon, E. Ng, R.L. Shapiro, R.S. Berman, A.C. Pavlick, F. Darvishian, P. Christos, M. Mazumdar, I. Osman, and D. Polsky Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma PLoS One 7 2012 e29336
23. F. Spagnolo, and P. Ghiorzo BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies Onco Targets Ther 8 2015 157 168
24. F. Spagnolo, P. Ghiorzo, and P. Queirolo Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma Oncotarget 5 2014 10206 10221
25. M. Lidsky, G. Antoun, P. Speicher, B. Adams, and R. Turley Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells J Biol Chem 289 2014 27714 27726
26. E.M. Goetz, M. Ghandi, D.J. Treacy, N. Wagle, and L.A. Garraway ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors Cancer Res 74 2014 7079 7089
27. D. Perna, and F.A. Karreth BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model Proc Natl Acad Sci U S A 112 2015 E536 E545
28. B. Miao, Z. Ji, and L. Tan EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma Cancer Discov 5 2015 274 287
29. A.M. Strohecker, and E. White Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism Autophagy 10 2014 384 385
30. J.M. Levy, and J.C. Thompson Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors Cancer Discov 4 2014 773 780
31. S. Martin, and A.M. Dudek-Perić Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in vemurafenib-resistant melanoma cells Biochem Pharmacol 93 2015 290 304
32. M. Michaelis, and F. Rothweiler Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression BMC Res Notes 7 2014 710 716
33. C.P. Wu, H.M. Sim, Y.H. Huang, Y.C. Liu, S.H. Hsiao, H.W. Cheng, Y.Q. Li, S.V. Ambudkar, and S.C. Hsu Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells Biochem Pharmacol 85 2013 325 334
34. M.A. Smit, and G. Maddalo ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma Mol Syst Biol 10 2014 772 786
35. G. Bollag, J. Tsai, J. Zhang, and C. Zhang Vemurafenib: the first drug approved for BRAF-mutant cancer Nat Rev Drug Discov 11 2012 873 886
36. F. Del Bufalo, and A. Carai Response of recurrent BRAFV600E mutated ganglioglioma to vemurafenib as single agent J Transl Med 12 2014 356 362
37. P. Jain, A. Polliack, and F. Ravandi Novel therapeutic options for relapsed hairy cell leukemia Leuk Lymphoma 4 2015 1 9
38. M. Das Thakur, and F. Salangsang Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Nature 494 2013 251 255
39. A.J. Dooley, A. Gupta, M. Bhattacharyya, and M.R. Middleton Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: Review of a case series Ther Adv Med Oncol 6 2014 262 266
40. S. Hu-Lieskovan, L. Robert, B. Homet Moreno, and A. Ribas Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges J Clin Oncol 32 2014 2248 2254
41. L.N. Kwong, and M.A. Davies Targeted therapy for melanoma: rational combinatorial approaches Oncogene 33 2014 1 9
42. https://clinicaltrials.gov.
43. R. Yaeger, A. Cercek, E.M. O'Reilly, and D.L. Reidy Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients Clin Cancer Res 21 2015 1313 1320